Sort
82,697 grants matching “vaccine development”
Applications of a robust, vector-free intracellular delivery platform for immune cells
$743,988Scott McNabb Loughhead · Sqz Biotechnologies Company, Inc. · R44 · FY2017 · GM
Protective immunity to typhoid
$743,924Stephen J McSorley · University Of Connecticut Sch Of Med/Dnt · P01 · FY2013 · AI
Mucosal immunity and heterologous protection induced by single-cycle SIV
$743,924David T Evans · Harvard Medical School · P01 · FY2007 · AI
Longitudinal Immunological Impact of SARS-CoV-2 Infection
$743,919Timothy Jensen Henrich · University Of California, San Francisco · R01 · FY2020 · AI
Prevention and Treatment of Pneumocystis Pneumonia
$743,912Karen A Norris · University Of Georgia · R01 · FY2020 · AI
Tfh dysfunction in HIV and Aging
$743,891Savita Pahwa · University Of Miami School Of Medicine · R01 · FY2023 · AG
Functional Definition of T Cell Receptors Associated with Protection from Pulmonary TB Infection and Disease
$743,817David M. Lewinsohn · Oregon Health & Science University · R01 · FY2025 · AI
Protective versus deleterious immune responses that impact vaccine efficacy against Staphylococcus aureus bloodstream infection
$743,809Hatice Karauzum · Integrated Biotherapeutics, Inc. · R01 · FY2020 · AI
HPV, HIV and Oral Microbiota Interplay in Nigerian Youth (HOMINY)
$743,801Modupe Coker · Rutgers Biomedical And Health Sciences · R01 · FY2022 · DE
Allergen Loaded Nanoparticles for Food Allergy Tolerance
$743,761Lonnie D Shea · University Of Michigan At Ann Arbor · R01 · FY2023 · AI
Design and Analysis of Vaccine Trials for Emerging Infectious Disease Threats
$743,713Natalie Exner Dean · University Of Florida · R01 · FY2018 · AI
B cell lineage directed rational vaccine strategies based on CAP256SU Env-Ab coevolution
$743,559Raiees Ahmad Andrabi · University Of Pennsylvania · R01 · FY2023 · AI
VIOLIN 2.0: Vaccine Information and Ontology LInked kNowledgebase
$743,543Yongqun He · University Of Michigan At Ann Arbor · U24 · FY2023 · AI
Modulation of innate and adaptive immunity of filoviruses in macaques
$743,530Thomas William Geisbert · Georgia State University · U19 · FY2017 · AI
Large Scale Synthesis of the Next Generation Synthetic Saponin Adjuvant TiterQuil
$743,432Philip O. Livingston · Adjuvance Technologies, Inc. · R44 · FY2018 · AI
POPULATION-BASED MOLECULAR EPIDEMIOLOGY OF TUBERCULOSIS
$743,430University Of California San Francisco · R01 · FY2000 · AI
Development of a novel adjuvant strategy enabled by modulation of the physical properties of fungal mannans
$743,329Ivan Zanoni · Boston Children'S Hospital · R01 · FY2024 · AI
Malaria parasite and vector genomics: transmission, pathology, and therapeutics
$743,302Daniel E Neafsey · Broad Institute, Inc. · U19 · FY2017 · AI
Development and Field Testing of a Novel Reservoir Targeted Antibiotic Against Borrelia burgdorferi
$743,299Linden T Hu · Tufts University Boston · R01 · FY2020 · AI
HIV and Hepatitis C Pathogenesis & The Human Genome
$743,251David L Thomas · Johns Hopkins University · R01 · FY2015 · DA
Miami Treatment and Prevention Clinical Trials Unit (CTU)
$743,160Dushyantha Jayaweera · University Of Miami School Of Medicine · UM1 · FY2019 · AI
A mechanistic understanding of tuberculosis progression through bacterial reporter strains
$743,107David G Russell · Cornell University · R01 · FY2018 · AI
Development of an improved, low-cost polio vaccine (Ir-IPV)
$743,104Gregory John Tobin · Biological Mimetics, Inc. · R44 · FY2017 · AI
Improving Influenza Vaccination Delivery Across a Health System by the Electronic Health Records Patient Portal
$743,070Peter G Szilagyi · University Of California Los Angeles · R01 · FY2022 · AI
Production and Characterization of Human Immunoglobulin Producing Goats for Diagnostic Reagents and Therapeutics
$743,067Hua Wu · Sab Capra, Llc · R42 · FY2020 · AI